IMCD N.V. (IMCD) Earnings Call Transcript
November 6, 2025
Earnings Call Speaker Segments
This is the IMCD conference call covering results for the first nine months of 2025, and our hosts today are Marcus Jordan, CEO, and Hans Kooijmans, CFO. During the opening portion of the call, everyone will be in listen-only mode, and a question-and-answer session will follow that. Should you want to pose a question, just press pound key five on your telephone keypad. At this point I'll hand things over to Marcus Jordan. Mr. Jordan, the floor is yours.
Thanks so much, Alba. Good morning, everyone, and a warm welcome. My name is Marcus Jordan, and joining me today is our CFO, Hans Kooijmans, for the 2025 First Nine Months Results, which came out in a press release earlier this morning. Conditions in the first nine months of 2025 were broadly marked by a difficult market environment stemming from ongoing macroeconomic uncertainty, especially regarding tariffs across all regions. That led to weaker demand in a number of markets, restricted visibility on orders, and just-in-time deliveries. Turning to the first nine months' figures, a summary of our financial results appears on slide four, where, given these persistently tough macroeconomic conditions, I'm pleased with how gross profit grew in the first nine months, rising 5% on a constant currency basis to EUR 927 million. That gain reflects a mix of organic performance, successful acquisitions, and resilient gross profit margins. EBITRA likewise rose 1% on a constant currency basis to EUR 394 million, and our cash flow of EUR 284 million came in somewhat lower than in the first nine months of 2024, reflecting a combination of slightly lower EBITRA and a modest rise in working capital investments.
Like we said on the half-year call, we're actively working to bring our inventory amounts back down to historical levels, but I also want to emphasize how important it is that, during these uncertain times, we have inventory on hand to meet our customers' demands. If we turn now to M&A, we announced four acquisitions in the first half of 2025, and in Q3 we were very happy to add another two. In August, we announced the acquisition of Tilmans in Italy, which operates across a broad range of markets, including coatings and construction, food and nutrition, and water treatment. Tilmans has 78 people and had a revenue of EUR 143 million in 2024. I'm very proud of this acquisition, as we become a real powerhouse for our partners, teams, and suppliers in Italy. In October, we also announced the acquisition of Don Young FT in South Korea, a company active in beauty and personal care. With 14 people and EUR 34 million in revenue, we strengthened our position in South Korea, which, as you know, is one of the most innovative and largest beauty and personal care markets in the world. On a full-year basis, these six acquisitions will add around EUR 340 million in revenue and 185 employees, based on their last full-year numbers before acquisition.
Turning to our business segments, the strongest results in the first nine months came from pharmaceuticals, food, and nutrition, while our beauty and personal care and industrial segments saw generally soft demand across all three regions. On the demand side, we receive many questions about Chinese competition in our various markets, and it is fair to say that during this year we have encountered more competition from China. Although our specialty-focused portfolio shields us to some degree, we have experienced some pricing pressure, mainly on the semi-specialty components of our portfolio, and particularly in the APAC and LATAM countries. It is worth emphasizing that Chinese competition is nothing new for us, and as we have done throughout IMCD's history, we routinely review the portfolio we hold in all countries and markets to make sure we remain competitive for the longer term and, where necessary, adapt our portfolio accordingly, once again keeping the company's long-term growth in mind. In summary, despite the continuing uncertainties in global trade and tariffs, our business model has demonstrated resilience during the first nine months of the year. We are stepping up our efforts further to drive cost-effectiveness and commercial excellence across the entire company and to ensure that we have the right people in the right positions for the future.
We're continuing to make our sales force stronger — both the people out in the field and the inside sales specialists. And at the same time, we're using our digital initiatives to improve efficiency in other parts of the business. Taken together, this is going to bring down the number of FTEs as we move ahead. Thanks to our adaptable, specialty-focused portfolio, our geographic and market diversity, and our advanced digital and supply chain capabilities, we're well positioned for what's ahead, and our confidence in the strength and long-term outlook of our asset-light business model remains unchanged. At this point I'd like to turn things over to Hans Kooijmans, our CFO, who will walk you through the numbers.
Thank you, Marcus, and good morning, ladies and gentlemen. As usual, I'll give a brief summary of IMCD's results for the first nine months before we move on to Q&A. Let me begin on page seven of the presentation. Here you can see that forex-adjusted revenue and gross profit both went up, by 6% and 5% respectively, compared with last year. Despite the challenging conditions that Marcus just mentioned, we still delivered a modest level of organic gross profit growth, plus a 4% increase stemming from the first-time inclusion of acquired businesses. Gross profit as a percentage of revenue dipped slightly to 25.2%, and roughly half of that 0.2% decrease comes from the negative impact of acquisitions — acquisitions whose gross profit margin on average is lower than the group average. In addition, we saw the usual fluctuations in our product mix, currency impacts, and changes in local market conditions. Forex-adjusted operating EBITRA rose 1% to EUR 394 million, and this increase came from an organic decline of 3% that was more than offset by the positive impact of the first-time inclusion of the acquisitions. Both reported EBITRA and conversion margin declined, and that is mainly because gross profit growth could not fully compensate for inflation-driven growth in our own costs.
I mean, if you look at own-cost growth, organic own-cost growth for the year to date has fallen to just under 4%. Relative to September 2024, our full-time headcount, once normalized for the impact of acquisitions, was slightly lower. Forex-adjusted net result, on the following line, was down 9%, and in our trading updates we typically don't provide a detailed breakdown of that difference. That said, it's reasonable to assume the key drivers mirror those in our half-year results: lower reported EBITRA and higher finance costs are the primary factors. Those elevated finance costs in year-to-date 2025 stem mainly from somewhat larger forex losses and smaller gains on fair value adjustments of various considerations. In addition, we have reported and will report further costs tied to one-off adjustments to the organization. Those extra cost items are partly offset by lower tax costs. As we close out the year, you should anticipate additional costs related to one-off adjustments to the organization that are higher than usual. As you know, and as we've said previously, we remain cost-conscious at all times and prudent about our cost structure. Still, as the market also indicates, current market conditions, along with opportunities arising from our digital investments, let us lower our fixed cost base and adapt the organization to shifts in market conditions.
Regarding free cash flow, we’re reporting a cash conversion margin of 71%, and that’s a bit below the figure for the same period last year. As we mentioned on our prior call, we implemented extra steps aimed at lowering our working capital investment, and with that we take care to hold enough inventory to meet customer requirements. On our prior call, when we went through the end-of-June numbers, we reported that working capital days came in six days above the same period last year. By the end of September, we had narrowed that gap to three days, and we’re confident that at year-end we’ll report a cash conversion ratio in the area of a high 80% or a low 90% figure. Turning to the next page, slide eight, you’ll see a summary of several key figures broken out across the regional operating segments. Looking at top-line and gross profit, as you can see, we achieved organic growth in all three regions despite these challenging market conditions. We also faced considerable currency headwinds when translating local results into EUR, with the largest effects in APAC and the Americas. That currency translation impact is straightforward to quantify and report as a separate line, but working out the operational effect of those currency fluctuations is more complicated.
Clearly, those shifts in currency values hurt us. In places where pricing is typically set in dollars while billing happens in the local currency. So it's reasonable to conclude that this year's currency movements had a negative effect on our results across LATAM, APAC, and a handful of EMEA countries. At the bottom of this slide, you'll see the EBITRA margin and the conversion margin by segment, and we show a negative trend in three out of the four segments. The sole positive exception is holdings, where the ratio of cost to revenue improved slightly thanks to lower holding cost. EMEA shows the largest EBITRA and conversion margin gap versus last year. As noted on the prior call, bear in mind that most of the global business group costs sit in the EMEA region, which then naturally results in a generally higher cost base. The largest swings in results over the year showed up in the Americas and Asia-Pacific. The Americas and APAC posted, respectively, positive 21% and 7% organic EBITRA growth in the first quarter, which reversed into minus 4% and minus 3% year-to-date September. Marcus already gave you some color on the backdrop.
Page nine gives you a summary of free cash flow at IMCD. Free cash flow came in EUR 16 million below the prior year on an absolute basis, and our cash conversion ratio stood at 71%. The key reasons for the gap versus last year were lower EBITRA and somewhat greater investment in working capital. As I noted earlier, we have confidence that at year-end we will deliver a cash conversion ratio in the neighborhood of a high 80% or low 90% figure. Moving to page 10, an update on net debt and leverage. Net debt at the close of September was near EUR 1.5 billion, a touch below the end of September a year ago and EUR 228 million above where it stood at the end of December. The rise in our net debt position year-to-date was driven, among other things, by a mix of positive operating cash flows on the one hand and cash outflows of EUR 281 million from acquisitions plus EUR 127 million in dividend payments on the other. Our reported leverage ratio, which includes the full-year effect of acquisitions completed, was 2.6 times EBITRA — comparable to the leverage calculated under the definitions in our loan documentation. Finally, on page 12, our outlook for 2025 is set out, and I take it everyone has already gone through the text in the press release.
So I won't go over it again out loud. With that, I'd like to turn things over to Al, and the operator will open the lines for questions.
Thank you very much. Ladies and gentlemen, we're ready to take your questions now. To ask one, just press the pound key and then 5 on your phone's keypad. Our first question is from Annelies Vermeulen at Morgan Stanley. Please go ahead.
Hello, good morning, Marcus, and good morning, Hans. There are two things I'd like to ask about, please. First, could you give us some detail on the way pricing moved during the quarter? Earlier in the year we discussed stabilization, but now I'm curious how tariff-driven inflation combined with a few of the competitive pressures you referred to is affecting pricing, and how that has played out versus what you expected. Second, on the Chinese supplier competition, I believe we covered this at the half-year. Could you say a bit about how it evolved in Q3? Has that competition intensified, especially as tariff noise has grown, and do you think it will carry on for the foreseeable future? On that point, you mentioned keeping the portfolio under review. Are there any structural changes you are weighing if we assume that competitive pressure persists? Thank you.
Good morning, Annelise, and thanks so much for your questions. On pricing, I think what we can tell you is that we did not observe any truly meaningful shift over the course of the quarter. What we have seen, I'd describe as somewhat more typical pricing conduct, with modest increases showing up in a few product lines. And tied to your second question, we keep encountering pricing pressure in specific areas and business lines within semi-specialty coming out of China. I would characterize it as nothing that has moved materially since the previous quarter. Turning to competitive pressure from China, once again, I would not describe the third quarter as showing a very large uptick relative to what has come before. Broadly speaking, competition this year has been greater than it was last year. It's also worth emphasizing, as I noted earlier, that competition from China is not a new phenomenon. Then, on the structural change and the way we evaluate the portfolio, it's important to note that our Asia sourcing offices have been operating in India and China for over 20 years. In the past, those offices concentrated heavily on certain product lines that were largely produced in those locations.
Pharmaceutical actives illustrates this well. As you might expect, those sourcing offices are occasionally also used by us to identify the white spots we have, especially in nations we may be newly entering. We keep a very close watch on what's going on among, say, Chinese manufacturers, reviewing our portfolio, while staying highly loyal to the long-term partners we have, and always — I think — keeping an eye on the company's long-term growth, ensuring we avoid knee-jerk reactions to what may be short-term market conditions. Once more, I believe the beauty of our business model lies in a very agile product portfolio. We're able to adapt wherever needed. Again, let's be cautious and make sure we're doing that with a very long-term view.
That is quite useful. I appreciate it.
Our following question is from Matthew Yates at Bank of America. Matthew, the floor is yours.
Hi, good morning, everybody. I’d like to pick up right where we left off on that theme of competitive pressure. If we look at how you performed in Asia, it would help to dig into that a bit more. The top line was roughly flat. That feels decent given the tariff uncertainty the world is dealing with right now. Then there’s the 13% organic decline in EBITRA. That points to some competitive pressure or investment you’re making to drive future growth. I’m not sure. Marcus, when you mention portfolio review, to me that just sounds like exiting business and accepting that some product lines are no longer profitable for IMCD to run. Is that a fair read? If so, how much of the portfolio are we talking about? Is there anything else you can do to kind of shore up the business model and address the pricing pressure you have given these challenges? I hear you saying it’s nothing new, but at the same time, it does feel like it’s getting more intense or speeding up. Thank you.
Alright. Good morning, Matthew. Perhaps I’ll start by addressing the first point and the Asia-Pacific figures. For me, the standout item there, Matthew, concerns India, where performance in the third quarter was, I’d say, quite soft. Looking a bit further into it, the biggest impact, I would say, comes from pharma. We all witnessed the discussions around pharmaceutical tariffs that happened in the third quarter, which created, I’d say, a fair amount of uncertainty generally. There was a large pharmaceutical exhibition in Frankfurt called CPHI last week. While there, we had the chance to talk with a wide range of both our suppliers and customers. Everyone, I think, observed the same pattern of softness during the third quarter. Nearly everyone also speaks with confidence that things will return to some form of normality in Q1. This, I believe, is a short-term matter. As for the idea of walking away from business, that is definitely not the situation. First, if you look again at the long-term supplier relationships we maintain, it’s also worth noting that among the partners we have, many of those partners hold assets in China as well.
They can stay competitive as well. When we discuss portfolio review, once more, there is nothing novel here. We continuously examine, nation by nation, where the white spots are. What ways can we reinforce the business? What ways can we reinforce the portfolio? Also examining — which, again, is nothing novel — whether there are business pieces or specific product ranges in which we cannot compete. Usually by that point such business has already declined or is quite small. It's more about examining how we can lift the business and get it growing once more going forward, instead of abandoning business that we already hold.
Much appreciated.
Suhasini Varanasi from Goldman Sachs has the next question. You're up.
Good morning, and thanks for taking my question. I have just a couple, please. Could you perhaps talk about how your discussions with customers are going? At this point, are you noticing any indications that volumes are stabilizing sequentially? Some detail on the order book would be useful as well. Looking at gross margins for this quarter, they've worsened pretty markedly compared with the first-half trends. You said M&A accounted for half of that, but as for the remainder, is that essentially the pricing pressure you experienced? Thank you.
To start with the customers and the stability of volumes or the outlook, I'd say that, unfortunately, there's no change when it comes to the visibility we have. The order book is still very volatile, I would say, with minimal forecasting and a lot of just-in-time deliveries. Unfortunately, I'd say there's no general improvement there. On the gross margin percentage, I think Hans already covered that, and I would say there's nothing exceptional there, a little bit of dilution from the M&A impact, maybe product mix to a certain extent, but I would say nothing material.
Thanks.
Our following question is from David Kerstens at Jefferies. You have the floor.
Good morning, gentlemen. I have two questions, please. First, regarding the stable organic revenues in the third quarter, that looks like a solid result against a much tougher comparative. I was wondering whether you could point to some product-market combinations where you're seeing sequential improvement versus the second quarter. The second question concerns the balance sheet, with leverage rising to 2.6 times EBITRA and the Tilmans acquisition not yet closed. How do you expect that leverage ratio to develop in the fourth quarter, toward year-end, and after Tilmans closes? Does that still leave you with enough headroom for further M&A as we go into 2026? Would you allow leverage to go higher temporarily given the short-term unfavorable market conditions? Thank you very much.
Morning, David. On stable organic growth, a lot of effort is clearly going on behind the scenes to deliver that. If one market stands out for stability, it would be food and nutrition. I wouldn't claim there's much difference from one quarter to the next, but among the various market segments, that one has been the steadiest and strongest for us this year. Turning to M&A and leverage, Hans?
David, morning — Hans here. Regarding leverage, I’d rather not forecast where that number lands at year-end, and you’ve got a fair point. There’s still a payment I have to make. I also have to complete Tilmans. We’re expecting to get that done during the final part of this quarter, assuming all the formalities are wrapped up. If and when it goes through, then yes, I’d expect leverage to sit around that 2.6 figure. That leaves ample capacity for more M&A. Working capital usually declines as we approach year-end, and the cash conversion ratio we’ve referenced ought to generate extra cash coming in. Our firepower doesn’t worry me in the slightest.
All right, that's great. That works well. Thanks a lot.
Our following question is from Nicole Manion with UBS. Nicole, you have the floor.
Good morning. I have just a single question, if I may. Could you expand a little on what you said regarding the cost base, and FTEs in particular? Clearly, there appears to be a nod toward how volatile the environment is right now, but I think you also tied it to digital initiatives that are ongoing, which might imply this is somewhat of a longer-term project. I'm not certain whether you can share further details here — whether this is something being examined across regions, and what falls within scope. Yes, any kind of color would be helpful. Thank you.
Thank you, Nicole. As I said, this isn’t a new thing, though it’s fair to say we’re stepping up our efforts to really push that cost-effectiveness while also ensuring we deliver premium customer service. As we’ve discussed previously, customer expectations are evolving, along with this omnichannel way of operating. For us, that means making it very critical to ensure we have highly skilled technical development resources on the road, visiting customers face-to-face, and also very highly qualified inside salespeople, so that no matter how a customer wants to interact, they have immediate contact and we can respond in a very timely, effective, and efficient manner. What we’re doing is really focused on ensuring we have the right people in the right roles to again be the leader from a sales excellence standpoint to drive long-term growth, while also using the digital tools we’re very proud of, essentially to optimize other areas of the business. I think if you look at just 1 example, through the use of AI and various topics, things like the marketing side, how we’re able to handle that and drive it in a more efficient way, I think that’s a good example.
Once more, this isn’t new for us, but it’s fair to say we’re stepping up our attention there, partly because of the fairly difficult market conditions we’re dealing with. Again, what matters, I think, is seeking growth over the long term.
Thanks — that's really useful. Appreciate it.
Our next question is from David Simmons with BNP Paribas. Go right ahead.
Hello, and thanks. I want to revisit gross profit for a moment. You cited what might be an effect from M&A and possibly one from mix. Given that you're working to reduce inventories and did a stronger job converting free cash flow in the third quarter, I'm wondering whether inventory has any bearing at all on gross profit margins. Perhaps this is partly an outlook question. Again on gross profit margins: we really didn't observe any pressure there during the first half, when they were flat year-on-year, yet in Q3 they fell 90 basis points. Would you expect a reversal over the coming quarters, or does that represent a new baseline, given the changed mix and the new M&A you've completed, for the next few quarters?
David, I genuinely get where you're coming from. When you examine IMCD's figures over time, the margin percentage tends to swing quite a bit from one quarter to the next, and this year is no different. Usually that comes from modest shifts in the product mix, with M&A in this instance dragging the overall margin percentage down somewhat. Certainly, on certain more commoditized products there was some pricing pressure here and there that had a bit of an effect, though that was already the case in the prior quarter. At the end of the day, permanently raising your margin percentage isn't really the point. Growing the absolute amount matters more. Our salespeople always aim for a target expressed as an absolute margin amount rather than a percentage target. Whether this is the new normal, I doubt it, but let's see what the future holds.
Thank you.
Moving on, our next question is from Eric Wilmer at Kempen. Please go ahead.
Good morning, everyone. I have a single question. Do the demand pressures that continue and the competitive pressures facing European manufacturers carry any consequences for how much outsourcing they engage in? A few manufacturers, I believe, including as of today, have announced fresh measures aimed at incremental cost savings. Might that in fact serve as one more avenue for outsourcing? With the Chinese presence expanding, does that hand you bargaining power over the suppliers you already have, perhaps to capture a bigger share of wallet? Thank you.
Thank you, Eric. This really varies from one supplier to the next. But as we've discussed previously, the overall direction is toward outsourcing a larger share. As our suppliers navigate these challenging market conditions, we do hear about a fair number of layoffs and headcount cuts on their side. At that point, I believe they value us even more as their outsourced sales and marketing partner. Yes, it's fair to say that, broadly speaking, more market uncertainty tends to create bigger opportunities, though it differs supplier by supplier. We're constantly talking with our current suppliers as well as prospective new ones to explore how we can broaden the relationships further, both geographically and across additional product lines.
That covers everything. Thank you.
Ladies and gentlemen, a quick reminder before we continue: should you like to pose a question, simply press the pound key and then the number five on your phone's keypad. We now have Carl Raynsford of Berenberg on the line. Please go ahead.
Good morning, everyone. I have just two questions, please. First, I wanted to ask about what you said regarding food and nutrition being the most stable end market segment this year. Before, judging by comments from yourselves and peers in the first half, pharma was viewed as, to paraphrase, by far the best-performing segment. Based on your comments, it feels as if there's been a significant slowdown in Q3, sort of more around food and nutrition now. Is that a fair assumption? The second question. I just wanted to focus on the comment around decreasing FTEs over time again. Presumably, you mean decreasing the absolute number even as revenue increases. This business has always been about relationships and sales and high service levels, and the AI opportunity in theory was useful for cross-selling. Could you discuss why you think you can maintain the same levels of sales and relationships alongside an increase in cross-selling and at the same time decrease the number of FTEs, enabled to be on the road, use omnichannel ways of working, and the same service levels, really? Or just considering your answer to Nicole's question earlier, is it more around the marketing side you're considering that? Yeah, thank you very much.
Morning, Karl. To start with the first question about food and nutrition and pharma: as I said earlier, in Q3 we did observe some softening in the pharma market, but mainly in the India space, driven by the tariff discussions. That, along with the feedback we received at CPHI last week, is why I made the comment about not including pharma in that. Overall, if you look at pharma across the year, it's still performing well versus last year. As I noted, there was a bit of softening in the third quarter, but we expect it to come back in the relatively short term. On service levels, I think it's really important to reiterate again that, if anything, we're investing further in the commercial organization and infrastructure. When you look at the FTE reduction, that definitely isn't about reducing the people out on the road. It's not the people interacting with customers or suppliers. It's really about looking at how we can bring better efficiency through digital tools across more of those, let's say, support functions. Hopefully that helps.
That really is reassuring to hear. Thank you, Marcus.
Stefano Toffano of ABN AMRO — ODDO has the final question. The floor is yours.
Yes, good morning, Marcus and Hans. There are two questions left from me. I apologize if the first has already been covered, but I missed it. On the Americas, could you perhaps give us a few highlights and shed some light on what you're seeing there regarding end markets and also the consumer? How is the consumer behaving? The second question is more general. I mean, over the years you've obviously witnessed quite a number of cycles. Is there anything different about this cycle versus past ones where you'd say, "Well, this might be here to stay. This will keep having an impact"? Or is it simply one of those cycles where you say, "Give it a take for whatever, one, two years, we will definitely go back to a normal environment"? Thank you.
Thank you, Stefano. Regarding the Americas question, the standout markets there — if you look at, say, softer performance — are the two countries we mentioned, and the reasons differ. For the US overall, on the demand side, consumer confidence is soft at present, in our view. Brazil, meanwhile, is one of the countries when we talk about Chinese competition, and perhaps stronger competition in that semi-specialty space in APAC and LATAM. Within LATAM, Brazil is definitely among the countries most affected there. Then on the cycle difference, I do believe this is very different from what we've seen historically, because we aren't going through a normal market cycle. There are these shockwaves that arrive. Through things such as the tariff discussions, where we're getting back to a more normal market cycle as we came through the end of last year and the start of Q1. You saw performance, I would say, normalizing more. The tariff shockwave and the uncertainty surrounding it, plus the continually changing messages about what the tariff percentage is, and also which products fall in the categories within the tariffs.
I believe what we really need is a bit of clarity and stability around those sorts of topics. With any luck, we'll return to a more typical kind of market cycle.
Thanks, I appreciate that.
So with that, because we’re limited on time, I’ll hand things back to Mr. Marcus for any closing remarks.
Thanks. Hans and I want to say a big thank you to everyone for being on the call this morning and for the questions you asked. We hope you all have a very good day. Many thanks.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete IMCD N.V. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to IMCD N.V. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.